Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
Budget 2025: Will India's robust GST kitty help Sitharaman stick to fiscal glide path?
India’s GST collections are set for a strong finish this fiscal year, driven by rural economic resurgence and efforts against ...